Clinical Trials Browser

Interventional × zalutumumab × Clear all

NCT00542308 2023-08-03

Zalutumumab in Non-curable Patients With SCCHN

Phase 2 Completed

90 enrolled 10 charts

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00707655 2023-08-03

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Phase 1/2 Terminated

8 enrolled 10 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT01054625 2023-08-03

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase 1/2 Completed

31 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00677924 2023-07-18

GEN206

Phase 1/2 Terminated

9 enrolled 8 charts

Gastrointestinal

Colorectal Neoplasms

NCT00093041 2023-06-28

Zalutumumab in Head and Neck Cancer

Phase 1/2 Completed

28 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00496652 2016-11-25

DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

Phase 3 Completed

Head and Neck Neoplasms

NCT00382031 2013-10-15

Zalutumumab in Patients With Non-curable Head and Neck Cancer

Phase 3 Completed

286 enrolled 12 charts

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00401401 2011-12-23

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Phase 1/2 Terminated

30 enrolled 13 charts

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00460551 2011-12-06

Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

Phase 2 Terminated

13 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT01449357 2011-10-10

Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung